{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:05:02Z","timestamp":1780506302987,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013965","name":"Eastern Virginia Medical School","doi-asserted-by":"publisher","award":["EVMS"],"award-info":[{"award-number":["EVMS"]}],"id":[{"id":"10.13039\/100013965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013965","name":"Eastern Virginia Medical School","doi-asserted-by":"publisher","award":["Macon & Joan Brock Virginia Health Sciences (VHS) CONRAD Director\u2019s Research Seed Funds"],"award-info":[{"award-number":["Macon & Joan Brock Virginia Health Sciences (VHS) CONRAD Director\u2019s Research Seed Funds"]}],"id":[{"id":"10.13039\/100013965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03427-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:54:07Z","timestamp":1778090047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation Development of Topical Inserts Containing Doxycycline and Doxycycline Combined with Tenofovir Alafenamide and Elvitegravir for the Prevention of Sexually Transmitted Infections"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-1777","authenticated-orcid":false,"given":"Vivek","family":"Agrahari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6637-5290","authenticated-orcid":false,"given":"M. Melissa","family":"Peet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-8337","authenticated-orcid":false,"given":"Jasmin","family":"Monpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-1845","authenticated-orcid":false,"given":"Rijo","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3231-7677","authenticated-orcid":false,"given":"Sriramakamal","family":"Jonnalagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0943-8099","authenticated-orcid":false,"given":"Pardeep K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-8287","authenticated-orcid":false,"given":"Meredith R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9641-1325","authenticated-orcid":false,"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"3427_CR1","unstructured":"Fact Sheet: Global HIV & AIDS statistics [Internet]. UNAIDS. 2025. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 22 Sep 2025."},{"key":"3427_CR2","unstructured":"Fact Sheet: Sexually transmitted infections (STIs) [Internet]. WHO. 2025. Available from: \nhttps:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis). Accessed 7 Oct 2025."},{"issue":"4","key":"3427_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/COH.0b013e32833a8844","volume":"5","author":"H Ward","year":"2010","unstructured":"Ward H, R\u00f6nn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305\u201310.","journal-title":"Curr Opin HIV AIDS"},{"key":"3427_CR4","unstructured":"National Academies of Sciences E, Medicine, Health, Medicine D, Board on Population H, Public Health P, et al. In: Crowley JS, Geller AB, Vermund SH, editors. Sexually Transmitted Infections: Adopting a Sexual Health Paradigm. Washington (DC): National Academies Press (US) Copyright 2021 by the National Academy of Sciences. All rights reserved.; 2021."},{"issue":"Suppl 6(Suppl S","key":"3427_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25355","volume":"22","author":"MS Cohen","year":"2019","unstructured":"Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019;22(Suppl 6(Suppl Suppl 6)):e25355.","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 6(Suppl S","key":"3427_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25346","volume":"22","author":"R Mwatelah","year":"2019","unstructured":"Mwatelah R, McKinnon LR, Baxter C, Abdool Karim Q, Abdool Karim SS. Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. J Int AIDS Soc. 2019;22(Suppl 6(Suppl Suppl 6)):e25346.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"3427_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1600-0897.2010.00942.x","volume":"65","author":"KH Mayer","year":"2011","unstructured":"Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol. 2011;65(3):308\u201316.","journal-title":"Am J Reprod Immunol"},{"key":"3427_CR8","unstructured":"Preventing Sexual Transmission of HIV. HIV.gov. https:\/\/www.hiv.gov\/hiv-basics\/hiv-prevention\/reducing-sexual-risk\/preventing-sexual-transmission-of-hiv. Accessed 7 Oct 2025."},{"issue":"9","key":"3427_CR9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/jphp.13107","volume":"71","author":"PK Yap","year":"2019","unstructured":"Yap PK, Loo Xin GL, Tan YY, Chellian J, Gupta G, Liew YK, et al. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. J Pharm Pharmacol. 2019;71(9):1339\u201352.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"3427_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","volume":"319","author":"J Riddell","year":"2018","unstructured":"Riddell J, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. Jama. 2018;319(12):1261\u20138.","journal-title":"Jama"},{"issue":"8","key":"3427_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","volume":"330","author":"R Chou","year":"2023","unstructured":"Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US preventive services task force. Jama. 2023;330(8):746\u201363.","journal-title":"Jama"},{"key":"3427_CR12","doi-asserted-by":"crossref","unstructured":"Boschiero MN, Sansone NMS, Matos LR, Marson FAL. Efficacy of doxycycline as preexposure and\/or postexposure prophylaxis to prevent sexually transmitted diseases: a systematic review and meta-analysis. Sexually Transmitted Diseases. 2025;52(2):65\u201372.","DOI":"10.1097\/OLQ.0000000000002082"},{"issue":"3","key":"3427_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"JM Molina","year":"2018","unstructured":"Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308\u201317.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"3427_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","volume":"42","author":"RK Bolan","year":"2015","unstructured":"Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98\u2013103.","journal-title":"Sex Transm Dis"},{"issue":"25","key":"3427_CR15","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","volume":"389","author":"J Stewart","year":"2023","unstructured":"Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, et al. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women. N Engl J Med. 2023;389(25):2331\u201340.","journal-title":"N Engl J Med"},{"key":"3427_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2339","volume":"383","author":"JH Tanne","year":"2023","unstructured":"Tanne JH. Us public health agency recommends prophylactic doxycycline to reduce STIs. BMJ. 2023;383:2339.","journal-title":"BMJ"},{"issue":"8","key":"3427_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25975","volume":"25","author":"JJ Dietrich","year":"2022","unstructured":"Dietrich JJ, Ahmed N, Webb EL, Tshabalala G, Hornschuh S, Mulaudzi M, et al. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe. J Int AIDS Soc. 2022;25(8):e25975.","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"3427_CR18","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1007\/s10461-022-03951-8","volume":"27","author":"BA Friedland","year":"2023","unstructured":"Friedland BA, Plagianos M, Savel C, Kallianes V, Martinez C, Begg L, et al. Women want choices: opinions from the Share.Learn.Shape global internet survey about multipurpose prevention technology (MPT) products in development. AIDS Behav. 2023;27(7):2190\u2013204.","journal-title":"AIDS Behav"},{"key":"3427_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jconrel.2024.11.062","volume":"377","author":"V Agrahari","year":"2025","unstructured":"Agrahari V, Peet MM, Chandra N, Ramalingam P, Gupta PK, Jonnalagadda S, et al. Formulation development of dual-compartment topical inserts combining tenofovir alafenamide and elvitegravir for flexible on-demand HIV prevention. J Control Release. 2025;377:842\u201354.","journal-title":"J Control Release"},{"key":"3427_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030348","author":"MM Peet","year":"2024","unstructured":"Peet MM, Agrahari V, Clark MR, Doncel GF. Preclinical and early clinical development of tenofovir alafenamide\/elvitegravir topical inserts for effective on-demand vaginal and rectal HIV prevention. Pharmaceutics. 2024;16(3):348.","journal-title":"Pharmaceutics"},{"key":"3427_CR21","doi-asserted-by":"publisher","first-page":"1130101","DOI":"10.3389\/fcimb.2023.1130101","volume":"13","author":"AR Thurman","year":"2023","unstructured":"Thurman AR, Ouattara LA, Yousefieh N, Anderson PL, Bushman LR, Fang X, et al. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. Front Cell Infect Microbiol. 2023;13:1130101.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"3427_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/infdis\/jiae211","volume":"230","author":"SA Riddler","year":"2024","unstructured":"Riddler SA, Kelly CW, Hoesley CJ, Ho KS, Piper JM, Edick S, et al. A phase 1 clinical trial to assess the safety and pharmacokinetics of a tenofovir alafenamide\/elvitegravir insert administered rectally for HIV prevention. J Infect Dis. 2024;230(3):696\u2013705.","journal-title":"J Infect Dis"},{"key":"3427_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080374","author":"MM Peet","year":"2019","unstructured":"Peet MM, Agrahari V, Anderson SM, Hanif H, Singh ON, Thurman AR, et al. Topical inserts: a versatile delivery form for HIV prevention. Pharmaceutics. 2019;11(8):374.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3427_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","volume":"58","author":"KN Agwuh","year":"2006","unstructured":"Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3427_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","volume":"15","author":"S Saivin","year":"1988","unstructured":"Saivin S, Houin G. Clinical pharmacokinetics of Doxycycline and Minocycline. Clin Pharmacokinet. 1988;15(6):355\u201366.","journal-title":"Clin Pharmacokinet"},{"key":"3427_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105037","author":"RE Haaland","year":"2024","unstructured":"Haaland RE, Fountain J, Edwards TE, Dinh C, Martin A, Omoyege D, et al. Pharmacokinetics of single dose doxycycline in the rectum, vagina, and urethra: implications for prevention of bacterial sexually transmitted infections. EBioMedicine. 2024;101:105037.","journal-title":"EBioMedicine"},{"issue":"8","key":"3427_CR27","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.3390\/app15084322","volume":"15","author":"S Ljubin-Sternak","year":"2025","unstructured":"Ljubin-Sternak S, Me\u0161trovi\u0107 T. Antimicrobial susceptibility testing in Chlamydia trachomatis: the current state of evidence and a call for more national surveillance studies. Appl Sci. 2025;15(8):4322.","journal-title":"Appl Sci"},{"key":"3427_CR28","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.2147\/IDR.S278020","volume":"13","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Xu WQ, Liu JW, Zhu XY, Chen SC, Han Y, et al. Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018. Infect Drug Resist. 2020;13:4475\u201386.","journal-title":"Infect Drug Resist"},{"key":"3427_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00979-20","author":"DG Edmondson","year":"2020","unstructured":"Edmondson DG, Wormser GP, Norris SJ. In vitro susceptibility of Treponema pallidum subsp. pallidum to doxycycline. Antimicrob Agents Chemother. 2020; 64(10):e00979-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"#cr-split#-3427_CR30.1","unstructured":"Garber DA, Peet MM, Jia H, Priode JH, Mitchell J, Dinh C, Edwards E, Haaland R, Agrahari V, Clark MR, Vishwanathan SA, McNicholl J, Doncel GF, Heneine W. Topical doxycycline inserts show high efficacy against vaginal chlamydia acquisition in Macaques [abstract]. In: Proceedings of (T-05) DoxyPEP Reflections [Internet]. CROI: 2025 Mar 9-12"},{"key":"#cr-split#-3427_CR30.2","unstructured":"San Francisco, CA. Available from: https:\/\/www.croiconference.org\/abstract\/577-2025\/. Accessed 7 Oct 2025."},{"issue":"2","key":"3427_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","volume":"59","author":"DH Owen","year":"1999","unstructured":"Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59(2):91\u20135.","journal-title":"Contraception"},{"issue":"4","key":"3427_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2164\/jandrol.04104","volume":"26","author":"DH Owen","year":"2005","unstructured":"Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl. 2005;26(4):459\u201369.","journal-title":"J Androl"},{"key":"3427_CR33","unstructured":"Stability Testing of New Drug Substances and Products Q1A(R2). International council for harmonisation of technical requirements for pharmaceuticals for human use. 2003. https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf."},{"issue":"1","key":"3427_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/10837450500464255","volume":"11","author":"GK Bolhuis","year":"2006","unstructured":"Bolhuis GK, Anthony Armstrong N. Excipients for Direct Compaction\u2014an Update. Pharm Dev Technol. 2006;11(1):111\u201324.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"3427_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1461-5347(99)00237-0","volume":"3","author":"M Jivraj","year":"2000","unstructured":"Jivraj M, Martini LG, Thomson CM. An overview of the different excipients useful for the direct compression of tablets. Pharm Sci Technol Today. 2000;3(2):58\u201363.","journal-title":"Pharm Sci Technol Today"},{"issue":"3","key":"3427_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/10837450.2013.775154","volume":"19","author":"HL Ohrem","year":"2014","unstructured":"Ohrem HL, Schornick E, Kalivoda A, Ognibene R. Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms? Pharm Dev Technol. 2014;19(3):257\u201362.","journal-title":"Pharm Dev Technol"},{"key":"3427_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102046","volume":"60","author":"M Kurakula","year":"2020","unstructured":"Kurakula M, Rao GSNK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): as excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. J Drug Deliv Sci Technol. 2020;60:102046.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3427_CR38","doi-asserted-by":"publisher","unstructured":"Bejaoui M, Galai H, Touati F, Kouass S. Multifunctional Roles of PVP as a Versatile Biomaterial in Solid State [Internet]. Dosage Forms - Innovation and Future Perspectives. IntechOpen; 2021. https:\/\/doi.org\/10.5772\/intechopen.99431.","DOI":"10.5772\/intechopen.99431"},{"issue":"11","key":"3427_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/jps.2600661112","volume":"66","author":"RC Shah","year":"1977","unstructured":"Shah RC, Raman PV, Sheth PV. Polyethylene glycol as a binder for tablets. J Pharm Sci. 1977;66(11):1551\u20132.","journal-title":"J Pharm Sci"},{"key":"3427_CR40","unstructured":"Kibbe AH. Handbook of pharmaceutical excipients. 3rd ed: American Pharmaceutical Association. Pharmaceutical Press; 2000."},{"issue":"3","key":"3427_CR41","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1208\/s12249-013-0007-5","volume":"14","author":"G Morin","year":"2013","unstructured":"Morin G, Briens L. The effect of lubricants on powder flowability for pharmaceutical application. AAPS PharmSciTech. 2013;14(3):1158\u201368.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3427_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2010.01.007","volume":"75","author":"J Wang","year":"2010","unstructured":"Wang J, Wen H, Desai D. Lubrication in tablet formulations. Eur J Pharm Biopharm. 2010;75(1):1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"3427_CR43","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.xphs.2015.12.019","volume":"105","author":"PM Desai","year":"2016","unstructured":"Desai PM, Liew CV, Heng PWS. Review of disintegrants and the disintegration phenomena. J Pharm Sci. 2016;105(9):2545\u201355.","journal-title":"J Pharm Sci"},{"issue":"5","key":"3427_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11095-017-2129-z","volume":"34","author":"D Markl","year":"2017","unstructured":"Markl D, Zeitler JA. A review of disintegration mechanisms and measurement techniques. Pharm Res. 2017;34(5):890\u2013917.","journal-title":"Pharm Res"},{"issue":"2","key":"3427_CR45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1073\/pnas.90.2.552","volume":"90","author":"JA Tamada","year":"1993","unstructured":"Tamada JA, Langer R. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci U S A. 1993;90(2):552\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3427_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104361","volume":"86","author":"CW Dobard","year":"2022","unstructured":"Dobard CW, Peet MM, Nishiura K, Holder A, Dinh C, Mitchell J, et al. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. EBioMedicine. 2022;86:104361.","journal-title":"EBioMedicine"},{"key":"3427_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.toxrep.2017.12.011","volume":"5","author":"S Ayehunie","year":"2018","unstructured":"Ayehunie S, Wang YY, Landry T, Bogojevic S, Cone RA. Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. Toxicol Rep. 2018;5:134\u201340.","journal-title":"Toxicol Rep"},{"key":"3427_CR48","unstructured":"Use and procurement of additional lubricants for male and female condoms: WHO\/UNFPA\/FHI360. World Health Organization. Advisory note. November 1, 2012. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/c0d0726b-e941-4d63-9647-fe2c2a52438a\/content.\u00a0Accessed 7 Oct 2025."},{"key":"3427_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac009","author":"R Truong","year":"2022","unstructured":"Truong R, Tang V, Grennan T, Tan DHS. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC-Antimicrobial Resistance. 2022;4(1):dlac009.","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"6","key":"3427_CR50","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/cid\/ciaf089","volume":"80","author":"OO Soge","year":"2025","unstructured":"Soge OO, Thibault CS, Cannon CA, McLaughlin SE, Menza TW, Dombrowski JC, et al. Potential impact of doxycycline post-exposure prophylaxis on tetracycline resistance in Neisseria gonorrhoeae and colonization with tetracycline-resistant Staphylococcus aureus and group A Streptococcus. Clin Infect Dis. 2025;80(6):1188\u201396.","journal-title":"Clin Infect Dis"},{"key":"3427_CR51","doi-asserted-by":"publisher","unstructured":"Makarova N, Singletary T, Peet MM, Kelley K, Johnson R, Agrahari V, et al. Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate\/elvitegravir in a macaque model of rectal SHIV infection. J Infect Dis. 2025.\u00a0https:\/\/doi.org\/10.1093\/infdis\/jiaf611.","DOI":"10.1093\/infdis\/jiaf611"},{"key":"3427_CR52","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7302a1","author":"LH Bachmann","year":"2024","unstructured":"Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recommendations and Reports. 2024;73(2):1-8.","journal-title":"MMWR. Recommendations and Reports"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03427-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03427-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03427-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:08:59Z","timestamp":1780502939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03427-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["3427"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03427-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (V.A., M.M.P., M.R.C., and G.F.D.) are named inventors on intellectual property related to the topical insert, including US Patent No. 12,370,203 B2 and Australian Patent No. 2019365204, as well as related pending applications and foreign counterparts. All other authors declare they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"204"}}